Biomarkers of Neurodegenerative Disorders Current Progress and Future Directions /
This book presents state-of-the-art knowledge regarding fluid and imaging biomarkers of neurodegenerative disorders, including Alzheimer disease and related dementias (ADRD). A cadre of the top experts in the field discuss the diagnostic and prognostic value of established and emerging biomarkers in...
Saved in:
| Corporate Author: | |
|---|---|
| Other Authors: | |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Cham :
Springer Nature Switzerland : Imprint: Springer,
2025.
|
| Edition: | 1st ed. 2025. |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/978-3-031-80849-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-031-80849-4 | ||
| 003 | DE-He213 | ||
| 005 | 20260810161108.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 250702s2025 sz | o |||| 0|eng d | ||
| 020 | |a 9783031808494 |9 978-3-031-80849-4 | ||
| 024 | 7 | |a 10.1007/978-3-031-80849-4 |2 doi | |
| 050 | 4 | |a RC321-580 | |
| 072 | 7 | |a PSAN |2 bicssc | |
| 072 | 7 | |a SCI089000 |2 bisacsh | |
| 072 | 7 | |a PSAN |2 thema | |
| 082 | 0 | 4 | |a 612.8 |2 23 |
| 245 | 1 | 0 | |a Biomarkers of Neurodegenerative Disorders |h [electronic resource] : |b Current Progress and Future Directions / |c edited by Rawan Tarawneh. |
| 250 | |a 1st ed. 2025. | ||
| 264 | 1 | |a Cham : |b Springer Nature Switzerland : |b Imprint: Springer, |c 2025. | |
| 300 | |a 1 online resource (XIII, 637 p. 39 illus.). |b 32 illus. in color. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 341 | 0 | |b PDF/UA-1 |2 onix | |
| 341 | 0 | |b Table of contents navigation |2 onix | |
| 341 | 0 | |b Single logical reading order |2 onix | |
| 341 | 0 | |b Short alternative textual descriptions |2 onix | |
| 341 | 0 | |b Use of color is not sole means of conveying information |2 onix | |
| 341 | 0 | |b Use of high contrast between text and background color |2 onix | |
| 341 | 0 | |b Next / Previous structural navigation |2 onix | |
| 341 | 0 | |b All non-decorative content supports reading without sight |2 onix | |
| 347 | |a text file |b PDF |2 rda | ||
| 505 | 0 | |a Section 1: Fluid and Imaging Markers of Pathologies associated with Alzheimer Disease or other Related Dementias -- Chapter 1: Fluid and Imaging Markers of Amyloid Pathology -- Chapter 2: Fluid Markers of Tau Pathology -- Chapter 3: Fluid and Imaging Markers of Synuclein Pathology -- Chapter 4: Fluid and Imaging Markers of Synaptic Injury -- Chapter 5: Fluid Markers of Neuronal and Axonal Injury -- Chapter 6: Fluid and Imaging Markers of Glial Reactivity -- Chapter 7: Fluid and Imaging Markers of Vascular Disease -- Section 2: Fluid and Imaging Markers of Neurodegenerative Disorders -- Chapter 8: Fluid and Imaging Markers of Alzheimer Disease -- Chapter 9: Fluid and Imaging Markers of Frontotemporal Lobar Degeneration -- Chapter 10: Fluid and Imaging Markers of Lewy body dementias -- Chapter 11: Fluid and Imaging Markers of Huntington’s Disease -- Section 3: Single and Integrated Omics Studies in Biomarker Discovery -- Chapter 12: Proteomics for Novel Biomarker and Drug Target Discovery in Alzheimer Disease -- Chapter 13: Genomics and Transcriptomics of Alzheimer Disease -- Section 4: Biomarkers in Clinical and Translational Alzheimer Disease Research -- Chapter 14: Biomarkers in Clinical Trials of Alzheimer Disease: An Overview -- Chapter 15: Biomarkers As Outcome Measures in Clinical Trials of Alzheimer Disease -- Chapter 16: Impact of Pre-analytical Factors on Fluid Biomarker Measurements in Alzheimer Disease -- Chapter 17: Mild Behavioral Impairment and Alzheimer’s Disease Biomarker Sample Enrichment for Clinical Trial Screening and Recruitment -- Section 5: Future Directions in Biomarker Research -- Chapter 18: Extracellular Vesicles as Biomarkers in Alzheimer Disease and Related Dementias -- Chapter 19: Sex Differences in Alzheimer Disease-Related Biomarkers and Dementia Risk -- Chapter 20: Imaging Markers of Amyloid and Tau -- Chapter 21: Novel Markers of Brain Endothelial Injury -- Epilogue: Expert Commentary on Future Directions or Epilogue: Sex/racial differences, standardization, and TDP-43. | |
| 520 | |a This book presents state-of-the-art knowledge regarding fluid and imaging biomarkers of neurodegenerative disorders, including Alzheimer disease and related dementias (ADRD). A cadre of the top experts in the field discuss the diagnostic and prognostic value of established and emerging biomarkers in ADRD, their ability to track or monitor disease progression or predict cognitive outcomes, and their potential as novel therapeutic targets. Biomarkers are discussed both in the context of specific disease mechanisms, including amyloid, tau, and synuclein pathologies, endothelial, vascular, neuronal, and synaptic injury, and glial reactivity as well as a wide spectrum of neurodegenerative disorders that encompass various pathologies. Multi-omics approaches in ADRD biomarker and drug target discovery including proteomics, genomics, and transcriptomics are covered. Importantly, the authors highlight the need to integrate biomarkers into various stages of ADRD drug development to accelerate drug discovery and approval. The book provides in-depth insight regarding significant progress in ADRD biomarker research over the last decade, addresses potential challenges in the translation of ADRD biomarkers into the clinic, and proposes important directions for future research. | ||
| 532 | 8 | |a Accessibility summary: This PDF has been created in accordance with the PDF/UA-1 standard to enhance accessibility, including screen reader support, described non-text content (images, graphs), bookmarks for easy navigation, keyboard-friendly links and forms and searchable, selectable text. We recognize the importance of accessibility, and we welcome queries about accessibility for any of our products. If you have a question or an access need, please get in touch with us at accessibilitysupport@springernature.com. Please note that a more accessible version of this eBook is available as ePub. | |
| 532 | 8 | |a No reading system accessibility options actively disabled | |
| 532 | 8 | |a Publisher contact for further accessibility information: accessibilitysupport@springernature.com | |
| 588 | |a Print version record. | ||
| 650 | 0 | |a Neurosciences. | |
| 650 | 0 | |a Diagnosis. | |
| 650 | 0 | |a Neurology . | |
| 650 | 0 | |a Neuropharmacology. | |
| 650 | 1 | 4 | |a Neuroscience. |
| 650 | 2 | 4 | |a Diagnosis. |
| 650 | 2 | 4 | |a Neurology. |
| 650 | 2 | 4 | |a Neuropharmacology. |
| 700 | 1 | |a Tarawneh, Rawan. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783031808487 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031808500 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031808517 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-031-80849-4 |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 912 | |a ZDB-2-237 | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||
| 950 | |a Focus Bundle Biomedical and Human Health Sciences (SpringerNature-85407) | ||